Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Issued
Ratios

Haemonetics (HAE) EBIAT (2016 - 2025)

Haemonetics has reported EBIAT over the past 17 years, most recently at $44.7 million for Q4 2025.

  • Quarterly results put EBIAT at $44.7 million for Q4 2025, up 19.33% from a year ago — trailing twelve months through Dec 2025 was $175.4 million (up 34.88% YoY), and the annual figure for FY2025 was $167.7 million, up 42.64%.
  • EBIAT for Q4 2025 was $44.7 million at Haemonetics, up from $38.7 million in the prior quarter.
  • Over the last five years, EBIAT for HAE hit a ceiling of $58.0 million in Q1 2025 and a floor of -$11.0 million in Q2 2021.
  • Median EBIAT over the past 5 years was $32.1 million (2022), compared with a mean of $27.5 million.
  • Biggest five-year swings in EBIAT: plummeted 162.65% in 2021 and later soared 546.27% in 2022.
  • Haemonetics' EBIAT stood at $14.9 million in 2021, then skyrocketed by 121.76% to $32.9 million in 2022, then decreased by 5.17% to $31.2 million in 2023, then increased by 20.02% to $37.5 million in 2024, then increased by 19.33% to $44.7 million in 2025.
  • The last three reported values for EBIAT were $44.7 million (Q4 2025), $38.7 million (Q3 2025), and $34.0 million (Q2 2025) per Business Quant data.